It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Host immune control plays a pivotal role in resolving primary hepatitis-B-virus (HBV) infections. The complex interaction between HBV and host immune cells, however, remains unclear. In this study, the transcriptional profiling of specimens from animals infected with woodchuck hepatitis virus (WHV) indicated TLR2 mRNA accumulation as most strongly impacted during WHV infection resolution as compared to other mRNAs. Analysis of blood transcriptional modules demonstrated that monocytes and B-cells were the predominantly activated cell types in animals that showed resolution of infection, which was similar to the response of TLR2-stimulated PBMCs. Further investigation of TLR2-stimulated B-cells pointed at interactions between activated TLR signaling, Akt-mTOR, and glucose metabolic pathways. Moreover, analysis of B-cells from Tlr2−/−, Trif−/−, Myd88−/−, and Trif/Myd88−/− mice challenged with HBV particles indicated B-cell function and glucose metabolism alterations is TLR2-MyD88-mTOR axis dependent. Overall, our study implicates B-cell TLR2 activation in HBV infection resolution.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University Hospital of Essen, University of Duisburg-Essen, Institute of Virology, Essen, Germany; Shanghai Public Health Clinical Center, Department of Infectious Diseases, Shanghai, China (GRID:grid.470110.3) (ISNI:0000 0004 1770 0943)
2 University Hospital of Essen, University of Duisburg-Essen, Institute of Virology, Essen, Germany (GRID:grid.470110.3); The Fifth People’s Hospital of Wuxi, Jiangnan University, Center of Clinical Laboratory, Wuxi, China (GRID:grid.258151.a) (ISNI:0000 0001 0708 1323); Bioinformatics and Computational Biophysics, University of Duisburg-Essen, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445)
3 University Hospital of Essen, University of Duisburg-Essen, Institute of Medical Microbiology, Essen, Germany (GRID:grid.5718.b)
4 Shanghai Public Health Clinical Center, Department of Infectious Diseases, Shanghai, China (GRID:grid.470110.3) (ISNI:0000 0004 1770 0943)
5 Bioinformatics and Computational Biophysics, University of Duisburg-Essen, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445)
6 University Hospital of Essen, University of Duisburg-Essen, Institute of Virology, Essen, Germany (GRID:grid.5718.b)